Manufacturing · Profile from Manufacturing Research Companion: Companies, Strategic Moves, and Technical Studies
Catalent
The Somerset, New Jersey contract development and manufacturing organisation (CDMO) that makes other companies' drugs — softgels and oral doses, biologics, gene therapies and, above all, sterile injectables filled into vials, syringes and cartridges. It began as Cardinal Health's pharmaceutical-services unit, which Blackstone bought in 2007 (~$3.3bn, reported) and renamed Catalent. It listed on the NYSE in July 2014, and spent 2017–21 building a biologics, gene-therapy and fill-finish network that filled COVID-19 vaccines. It then ran into FDA inspection findings at its Brussels and Bloomington fill-finish plants (2021–23), an activist campaign by Elliott (2023) and, in December 2024, a ~$16.5bn take-private by Novo Holdings, the controlling shareholder of Novo Nordisk. Novo Nordisk bought the three fill-finish sites it needed for Wegovy and Ozempic. Catalent's manufacturing story is that a contract manufacturer's value is quality and capacity in the right place, and a buyer who needs that capacity badly enough will buy it outright — even with its quality problems attached.
At a glance
- Founded
- As Catalent Pharma Solutions, 2007, when Blackstone bought Cardinal Health's Pharmaceutical Technologies and Services unit (~$3.3bn, reported — equal to Healthcare's Cardinal Health files); roots in R.P. Scherer (softgels, bought by Cardinal in 1998) and other Cardinal manufacturing businesses
- Headquarters
- Somerset, New Jersey
- Ownership / structure
- Private, owned by Novo Holdings since 18 Dec 2024 (~$16.5bn EV, $63.50 a share cash); NYSE: CTLT from 31 Jul 2014 to Dec 2024
- Leadership
- Alessandro Maselli, CEO at the time of the Novo deal (Healthcare KB; expected to remain, 2024 coverage); later leadership not confirmed (verify)
- Business lines
- Biologics (cell lines, drug substance, fill-finish, gene therapy); Pharma and Consumer Health (softgels, oral solids, inhaled and other dose forms); clinical supply services (segment names as of 2023–24, from memory, verify)
- Scale
- ~$4bn+ revenue before the take-private (reported, Healthcare KB); the three sites sold to Novo Nordisk (Anagni, Italy; Bloomington, Indiana; Brussels, Belgium) for ~$11bn (Healthcare KB) were among its largest fill-finish plants; Bloomington had ~1,800 positions in Mar 2026 under Novo (Bloomberg Law)
- Plants (US, selected)
- Bloomington, Indiana (sterile fill-finish and biologics; Catalent-owned 2017–2024, now Novo Nordisk); Baltimore-area gene-therapy sites (ex-Paragon, from memory for locations, verify); Madison, Wisconsin (biologics, from memory, verify); St. Petersburg, Florida (softgels, from memory, verify)
- Signature moves (incl. failures)
- Blackstone carve-out (2007); IPO (2014); Cook Pharmica and Bloomington (2017); Paragon gene therapy (2019, $1.2bn); COVID-19 vaccine fill-finish (2020–21); Brussels and Bloomington FDA findings (2021–23, failure); Elliott and the strategic review (2023); the Novo Holdings take-private and the three-site sale to Novo Nordisk (2024)
8 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
2007
Blackstone Carve Out from Cardinal
Financing / private-equity carve-out (leveraged buyout of a corporate division)
2014
IPO
IPO (private-equity exit route and deleveraging)
2017
Cook Pharmica and Bloomington
Acquisition (biologics drug substance and sterile fill-finish capacity)
2019
Paragon Gene Therapy
Acquisition / technology bet (viral-vector manufacturing for gene therapies)
2020
COVID Vaccine Fill Finish
Customer contracts and capacity commitment (pandemic vaccine drug substance and fill-finish)
2021
Brussels and Bloomington Quality Failures
Quality failure (FDA Form 483 observations at the two most strategic fill-finish sites; customer approval delays and supply interruptions)
2023
Elliott and the Strategic Review
Activism and governance change leading to a sale process
2024
Novo Holdings Take Private
Take-private by a customer's controlling shareholder / vertical integration (three fill-finish sites to Novo Nordisk)